Arinna Lifesciences has a portfolio of over 60 brands in chronic therapies and is among the few domestic formulations companies focused primarily on CNS-related treatments. The company operates with more than 4,000 prescribers supported by a distribution network of distributors, stockists and retail pharmacies across India.
The acquisition is aimed at advancing Rubicon’s strategy of leveraging its intellectual property and chronic products portfolio to expand in key therapeutic areas, particularly CNS, which remains a core focus segment.
Also Read: Rubicon Research shares can rally 54%, Motilal Oswal projects in ‘bull case’ scenario
Arinna’s distribution network is expected to provide access to patients and prescribers in India for Rubicon’s differentiated offerings, including specialty products and drug-device combinations.
The transaction values Arinna at an enterprise value of ₹200 crore on a cash and debt-free basis. After adjustments for net cash and other factors, the purchase consideration for the 85% stake has been set at approximately ₹175.92 crore for a secondary acquisition, translating into a price of ₹158.53 per share.
The final consideration remains subject to adjustments at closing. For the nine months ended December 31, 2025, Arinna reported provisional revenue of ₹56.7 crore and EBITDA of ₹9.5 crore.
Also Read: Rubicon Research shares make stellar debut, list at 28% premium over issue price
The deal is expected to close within 30 days, subject to satisfaction of agreed conditions precedent. Post completion, Arinna’s founder, Vivek Seth, will retain a 15% stake and continue as Managing Director.
Rubicon Research stated that the acquisition aligns with its approach of expanding through strategic transactions and leveraging its capabilities in research, development, manufacturing and commercialisation of differentiated pharmaceutical products.
Rubicon Research operates a portfolio of 80+ pharmaceutical products across multiple therapeutic areas, including CNS. The company has globally inspected manufacturing facilities in India approved by regulators, including the US FDA, UK MHRA and Australian TGA. It also maintains an R&D team of over 200 scientists across development centres in Mumbai and Toronto.
Parag Sancheti, Rubicon’s Chief Executive Officer, said, “The past decade has demonstrated the effectiveness of Rubicon’s playbook of R&D innovation, execution rigour, and impeccable compliance standards, which enabled us to scale our US revenues by over 32x from FY15 to FY25 while delivering best-in-class return ratios.
Also Read: General Atlantic trims stake in Rubicon Research ahead of IPO, raises ₹140 crore
Arinna now provides us with a launchpad for deploying this playbook in the Indian domestic formulations market. Strategic M&A has always been integral to Rubicon’s strategy, and our confidence stems from having successfully integrated and scaled acquisitions to foray into new segments such as US-branded speciality in 2024 and nasal products development in 2020. I am pleased to welcome Vivek and the Arinna team to the Rubicon family.”
Shares of Rubicon Research Ltd ended at ₹819.95, up by ₹0.35, or 0.043%, on the BSE.
